Scarica l'app Stockscreener
0.8256
6.99%
-0.062
Dopo l'orario di chiusura:
.82
-0.0056
-0.68%
Precedente Chiudi:
$0.8876
Aprire:
$0.89
Volume 24 ore:
60,996
Relative Volume:
0.13
Capitalizzazione di mercato:
$66.75M
Reddito:
-
Utile/perdita netta:
$-30.15M
Rapporto P/E:
-0.9073
EPS:
-0.91
Flusso di cassa netto:
$-31.63M
1 W Prestazione:
-0.70%
1M Prestazione:
-5.32%
6M Prestazione:
-66.30%
1 anno Prestazione:
-28.21%
Intervallo 1D:
$0.821
$0.895
Intervallo di 1 settimana:
$0.78
$0.895
Portata 52W:
$0.77
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Nome
Context Therapeutics Inc
Settore
Industria
Telefono
267-225-7416
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Confronta CNTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.8256 | 66.75M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-11-25 | Iniziato | D. Boral Capital | Buy |
| 2024-05-16 | Iniziato | Piper Sandler | Overweight |
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.33 Average PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Employees - MSN
Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% – Time to Buy? - Defense World
Biotech Giant Context Therapeutics Lures Talent with Sweet Stock Rewards - Elblog.pl
Context Therapeutics Awards Buzzy Stock Options to New Talent, Poised for Tumor-Targeting Breakthroughs - Smartphone Magazine
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Strengthens Team with Strategic Equity Compensation Package - StockTitan
CNTX’s Stock Journey: What Investors Need to Know About Context Therapeutics Inc’s Performance - The InvestChronicle
Context Therapeutics to Showcase at Top 2025 Investor Conferences - MSN
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Centrexion stock hits 52-week low at $0.79 amid market challenges - MSN
Centrexion stock hits 52-week low at $0.9 amid market challenges - MSN
Context Therapeutics Inc (CNTX) Stock: A SWOT Analysis - The News Heater
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MyChesCo
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Centrexion stock hits 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Unpacking Q3 Earnings: KLA Corporation (NASDAQ:KLAC) In The Context Of Other Semiconductor Manufacturing Stocks - Yahoo Finance
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Context Therapeutics appoints new chairman Andy Pasternak By Investing.com - Investing.com Australia
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages - Defense World
Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Context Therapeutics Inc Azioni (CNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):